Vaccine Development Against Melioidosis

2Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Melioidosis in an infectious disease of humans and animals caused by the bacterium Burkholderia pseudomallei. Melioidosis is often considered a disease of the tropics, but recent data suggests that B. pseudomallei is distributed worldwide and the disease is likely largely underestimated. B. pseudomallei is inherently resistant to many antibiotics, which complicates treatment, particularly in low-resource countries. There is currently no licensed vaccine to prevent melioidosis. Fortunately, there has been significant progress over the last decade in our understanding of B. pseudomallei pathogenesis and host immunity. This has been paralleled by the discovery and testing of promising vaccine candidates against melioidosis. Collectively, these scientific advances spark optimism that licensure of a safe and effective vaccine is achievable.

Cite

CITATION STYLE

APA

Galeas-Pena, M., & Morici, L. A. (2023). Vaccine Development Against Melioidosis. In Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis (pp. 327–344). Springer International Publishing. https://doi.org/10.1007/978-3-031-24355-4_15

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free